Lysostaphin

10/01/2020 - "Our study suggests that lysostaphin, coupled with other treatment modalities, can decrease MRSA infection short-term but do not completely eradicate MRSA in the long-term. "
01/01/2020 - "This "deimmunized" lysostaphin dampened human T cell activation, mitigated ADA responses in human HLA transgenic mice, and enabled safe and efficacious repeated dosing during a 6-week longitudinal infection study. "
12/01/2011 - "The goals of this study were to determine if LS adhered to porcine mesh (PM) can impact host survival, reduce the risk of long-term PM infection, and to analyze lysostaphin bound PM (LS-PM) mesh-fascial interface in an infected field. "
01/01/2020 - "By mitigating T cell-driven antidrug immunity, deimmunized lysostaphin may enable safe, repeated dosing to treat refractory MRSA infections."
05/21/2015 - "In contrast, while wild-type lysostaphin was efficacious against the initial MRSA infection, it failed to clear subsequent bacterial challenges that were coincident with escalating anti-drug antibody titers. "

04/01/2012 - "Chimeric phage lysins act synergistically with lysostaphin to kill mastitis-causing Staphylococcus aureus in murine mammary glands."
02/01/2009 - "Transgenic cows secreting over 3 microg of lysostaphin/ mL of milk are protected against mastitis caused by Staphylococcus aureus, but it is unknown if active lysostaphin persists through dairy processing procedures or affects the production of fermented dairy foods. "
10/01/2005 - "Staphylococcus aureus, a major mastitis pathogen, is exquisitely sensitive to lysostaphin. "
04/01/2005 - "aureus mastitis appears to be achievable with as little as 3 micrograms/ml [corrected] of lysostaphin in milk. "
03/01/2004 - "We demonstrate that while the lysostaphin gene can be introduced to the mammary gland using an adenoviral-mediated gene transfer technique, the strong immune response that it provokes makes the approach unsuitable for combating mastitis."

01/01/2001 - "Lysostaphin expression in mammary glands confers protection against staphylococcal infection in transgenic mice."
04/01/2023 - "Therefore, this unique property indicates the high ability of lysostaphin in the treatment of staphylococcal infections and is considered as an anti-staphylococcal agent. "
01/01/2021 - "These data indicated that the non-glycosylated lysostaphin 127A and 127A232Q may be a promising therapeutic agent against MDR staphylococcal infections."
01/01/2020 - "Lysostaphin causes rapid cell lysis and disrupts biofilms, and is therefore a therapeutic agent of choice to eradicate staphylococcal infections. "
05/01/2014 - "Lysostaphin represents a promising therapeutic agent for the treatment of staphylococcal infections, in particular those of methicillin-resistant Staphylococcus aureus (MRSA). "

06/01/2001 - "Lysostaphin is effective in treating experimental endophthalmitis mediated by MRSA."
06/01/2001 - "Lysostaphin is effective in treating methicillin-resistant Staphylococcus aureus endophthalmitis in the rabbit."
12/01/2002 - "A single intravitreous injection of lysostaphin (0.1%) sterilized all eyes of immunized and nonimmune rabbits with endophthalmitis. "
06/01/2001 - "To determine the effectiveness of lysostaphin treatment of experimental endophthalmitis caused by methicillin-resistant Staphylococcus aureus (MRSA). "
03/01/2006 - "The effectiveness of lysostaphin therapy was tested in an experimental model of endophthalmitis by intravitreally injecting log phase bacteria (100 colony-forming units; cfu) into rabbit eyes (n = 3 eyes per group). "

05/01/1992 - "The results showed that the mortality and incidence of bacterial isolation in wounds were 17.2% and 8.3%, respectively, in mice treated by lysostaphin, and the figures were significantly lower than that treated by SD-Ag (40.6% and 100%) or base (44.1% and 94.7%). "
04/01/1994 - "In order to control wound MRSA infection, Lysostaphin which is active against these organisms could be used as a topical antimicrobial."
05/01/1992 - "The effect of lysostaphin on the burn wounds infected with Staphylococcus aureus was studied in mice. "
10/01/2020 - "Topical lysostaphin may be more useful clinically for superficial nonimplant associated wounds in which the lytic enzyme has better access to the infected tissue."
01/01/2019 - "The bactericidal effect of lysostaphin coupled with liposomal vancomycin as a dual combating system applied directly on methicillin-resistant Staphylococcus aureus infected skin wounds in mice."